What is the HbA1c (hemoglobin A1c) reduction by doses of Mounjaro (tirzepatide)?

From the Guidelines

Mounjaro (tirzepatide) provides significant HbA1c reductions, with the 5mg dose reducing HbA1c by approximately 1.8-2.0%, the 10mg dose by about 2.0-2.2%, and the 15mg dose by approximately 2.3-2.5% from baseline, as observed in clinical trials 1.

Key Points

• The HbA1c reductions are generally observed over a 40-52 week treatment period in patients with type 2 diabetes.
• Mounjaro works through dual GIP and GLP-1 receptor agonism, which improves insulin secretion, reduces glucagon levels, slows gastric emptying, and decreases appetite.
• For optimal results, Mounjaro should be initiated at 2.5mg once weekly for 4 weeks, then increased gradually to the target dose.
• Patients should administer it subcutaneously on the same day each week and can inject it in the abdomen, thigh, or upper arm.
• The medication should be used alongside diet and exercise for maximum effectiveness.
• Side effects may include nausea, vomiting, and diarrhea, which often improve over time as the body adjusts to the medication.

Dosage and Administration

• The recommended dosage of Mounjaro is 2.5mg, 5mg, or 10mg administered subcutaneously once weekly.
• The dosage should be increased gradually to minimize gastrointestinal side effects.

Mechanism of Action

• Mounjaro is a dual GIP and GLP-1 receptor agonist, which improves insulin secretion, reduces glucagon levels, slows gastric emptying, and decreases appetite.
• This mechanism of action leads to improved glycemic control and weight loss.

Clinical Trials

• Clinical trials have demonstrated the efficacy and safety of Mounjaro in reducing HbA1c levels and improving glycemic control in patients with type 2 diabetes 1.
• The trials have also shown that Mounjaro is generally well-tolerated, with common side effects including nausea, vomiting, and diarrhea.

From the FDA Drug Label

Treatment with MOUNJARO 10 mg and 15 mg once weekly for 52 weeks resulted in a statistically significant reduction in HbA1c compared with insulin glargine once daily (see Table 6) Table 6: ... MOUNJARO5 mgMOUNJARO10 mgMOUNJARO15 mg HbA1c (%) Baseline (mean) 8.5 8.5 8.6 8.5 Change at Week 52b-1.4 -2.1 -2.3 -2. 4 Difference from insulin glargineb (95% CI) -- -0.7c (-0.9, -0.6) -0.9c (-1.1, -0.8) -1.0c (-1.2, -0.9)

The HbA1c reduction by doses of Mounjaro are:

• MOUNJARO 5 mg: -2.1%
• MOUNJARO 10 mg: -2.3%
• MOUNJARO 15 mg: -2.4% 2

From the Research

HbA1c Reduction by Doses of Mounjaro

• The HbA1c reduction by doses of Mounjaro (tirzepatide) is as follows:
  • 5 mg:
    • Mean HbA1c reduction of 1.87% at 40 weeks 3
    • Mean HbA1c reduction of 1.93% at 52 weeks 4
  • 10 mg:
    • Mean HbA1c reduction of 1.89% at 40 weeks 3
    • Mean HbA1c reduction of 2.20% at 52 weeks 4
    • Mean HbA1c reduction of 2.43% at 52 weeks 5
  • 15 mg:
    • Mean HbA1c reduction of 2.07% at 40 weeks 3
    • Mean HbA1c reduction of 2.37% at 52 weeks 4
    • Mean HbA1c reduction of 2.58% at 52 weeks 5
• The studies also compared the efficacy of tirzepatide with other treatments, such as insulin glargine and insulin degludec, and found that tirzepatide resulted in greater HbA1c reductions 5, 4
• The safety profile of tirzepatide was also evaluated, and the most common adverse events were mild to moderate gastrointestinal events, including nausea, diarrhea, and vomiting 5, 4, 3, 6